Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06262880 · ClinicalTrials.gov registry record · NA

Dietary Supplementation on Gastrointestinal Barrier Function

A NA study of Intestinal Permeability, sponsored by Brightseed.

Recruiting
Registry status
NA
Development phase
126
Enrollment target
1
Study location

NCT06262880 is a NA study of Intestinal Permeability that is actively recruiting participants, run by Brightseed. The registered enrollment target is 126 participants, above the 24-participant average among 3 other Intestinal Permeability trials with a reported enrollment target (425% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06262880, a NA study of Intestinal Permeability, is actively recruiting participants, sponsored by Brightseed.

RECRUITING
Registry status
NA
Development phase
126 participants
Enrollment target
1
Study location

Study Summary

The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels on parameters of gastrointestinal (GI) health in otherwise generally healthy adults with risk factors (high BMI and waist circumference) for increased GI permeability. The primary hypothesis is that supplementation with plant derived phenolics will improve gut health compared to placebo.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT plant derived phenolics
  • OTHER Microcrystaline cellulose (MCC)

Study Locations (1)

Illinois

  • Biofortis - Addison

Trial Details

FieldValue
Enrollment Target 126 participants
Start Date 2024-02-06
Est. Completion 2025-02-06
Phase NA

Sponsor

Brightseed

3 total trials

What the Registry Record Tells You About NCT06262880

The ClinicalTrials.gov registry entry for NCT06262880 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 126 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 24-participant average among 3 other Intestinal Permeability trials with a reported enrollment target (425% higher). The listed sponsor is Brightseed, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Intestinal Permeability appearing as the primary indexed condition, and to 2 interventions - of which plant derived phenolics is the first listed.

NCT06262880 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.

Frequently Asked Questions

What is clinical trial NCT06262880 about?

NCT06262880 is a clinical study titled "Dietary Supplementation on Gastrointestinal Barrier Function". The purpose of the current study is to examine the effects of a dietary supplement containing plant derived phenolics at two different dose levels on parameters of gastrointestinal (GI) health in otherwise generally healthy adults with risk factors (high BMI and waist circumference) for increased GI...

What is the current status of trial NCT06262880?

This trial is currently recruiting. It is a NA study. The enrollment target is 126 participants. The study started on 2024-02-06. Estimated completion is 2025-02-06.

What conditions does trial NCT06262880 study?

This clinical trial studies the following conditions: Intestinal Permeability.

What interventions are being tested in trial NCT06262880?

The interventions under investigation include: plant derived phenolics (DIETARY_SUPPLEMENT), Microcrystaline cellulose (MCC) (OTHER).

Who is sponsoring clinical trial NCT06262880?

This trial is sponsored by Brightseed, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06262880 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intestinal Permeability

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.